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1. GENERAL INTRODUCTION 
 
1.1 Cancer: an overview 
Cancer is a leading cause of death worldwide. In normal tissue when the cells 
become old or damaged, they undergo apoptosis. In healthy tissue, the ratio between 
cell growth and cell death is in balance but it is completely lost in cancer. Cancer is 
essentially a genetic disease; the DNA can get damaged, acquiring mutations that 
affect normal cell growth, division and apoptosis. When this occurs, cells may start to 
grow uncontrollably and form a mass of tissue called tumor (1). Multiple types of 
cancer susceptibility genes have been identified. Although they differ in various 
tumors, the loss or abnormal functions of them will render most cancers to acquire 
the same set of capabilities during their development. These capabilities are: 1. self-
sufficiency in growth signals; 2. evading apoptosis; 3. insensitivity to antigrowth 
signals; 4. tissue invasion and metastasis; 5. inducing angiogenesis; and 6. limitless 
replicative potential (2). Cancer susceptibility genes can be generally categorized into 
three classes-gatekeepers, caretakers and landscapers (3). 
 
1.1.1 Gatekeepers 
Gatekeepers include oncogenes and tumor suppressor genes (4). The mutations of 
both of them operate similarly at the physiological level: they drive the neoplastic 
process by increasing tumor cell number through the stimulation of cell growth or the 
inhibition of cell death or cell cycle arrest (5). 
 
Oncogenes 
Oncogenes are frequently activated by gain of function mutations or fusions with 
other genes, or they are aberrantly expressed due to amplification, increased 
promoter activity, or protein stabilization (6), hence they play important roles in 
diverse signaling pathways that are involved in various stages of human cancer 
initiation, progression, angiogenesis and metastasis (4). An activating somatic 
mutation in one allele is generally enough to confer a selective growth advantage on 
the cell. A large number of cellular oncogenes have been identified to play a role in 
colorectal cancer, such as KRAS, MYC, SRC, β-catenin, BRAF. Systematic 
mutational analyses showed that a minimum of 30% of CRCs contain at least one 
mutation in the tyrosine kinase family (7), and 32% of CRCs contain a mutation in the 
PIK3CA gene (8). 
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Tumor suppressor genes 
As the name indicates, tumor suppressor genes’ function is to suppress neoplastic 
cell growth. Mutation in these genes compromises this growth-suppressor 
mechanism by removing the inhibitions from the cell and result in uncontrolled 
growth. Examples are the genes Rb1 (the first isolated human tumor suppressor 
gene) p53 and p16. Tumor suppressor genes regulate diverse cell activities, 
including cell cycle checkpoint responses, detection and repair of DNA damage, 
protein ubiquitination and degradation, mitogenic signaling, cell specification, 
differentiation and migration, and tumor angiogenesis (9). Mutations (both point 
mutations and deletions) are not the only way through which a tumor suppressor 
gene can be inactivated. In recent years, it has become obvious that epigenetic 
changes, and haplo-insufficiency, can also help to switch off tumor suppressor 
genes.  
 
1.1.2 Caretakers 
Caretakers, or stability genes, act to maintain the genomic integrity of the cell by 
regulating DNA repair mechanisms, chromosome segregation, and cell cycle 
checkpoints (3). Caretaker defects lead to genetic instabilities that contribute to the 
accumulation of mutations in other genes, such as oncogenes and tumor suppressor 
genes that directly affect cell proliferation and survival, thus promoting tumorigenesis 
indirectly (10). 
 
1.1.3 Landscaper 
Landscaper defects do not directly affect cellular growth, but generate an abnormal 
stromal environment that contributes to the neoplastic transformation of cells (10). 
Their dysfunction or deregulation can disrupt normal tissue homeostasis, reduce host 
immune surveillance and defense, induce angiogenesis and inflammation, and 
promote tumor growth and migration (11). Some examples of landscaper genes are 
metalloproteinases (MMPs) uroplasminogen activator (uPA), friboblast growth factor-
2 (FGF-2) and platelet-derived growth factor (PDGF).  
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1.2 General background on colorectal cancer 
 
The colon is part of the digestive system, which is responsible for the final stages of 
the digestive process. The colon consists of ~10 crypts, each of which contains 
several thousand differentiated cells and a small number (between 1 and 10) of stem 
cells. Stem cells reside at the bottom of the crypts and divide slowly and 
asymmetrically, whereas differentiated cells divide rapidly and travel to the top of the 
crypt, where they undergo apoptosis. Each day, a total of approximately 10 cells are 
shed by the colon and have to be replaced, and each cell division represents a risk 
for cancer because of the mutational events that can occur during normal DNA 
replication and chromosome segregation (12). Colorectal cancer is the third most 
common cause of cancer-related death in the western world. Majority of CRC arises 
from malignant transformation of an adenomatous polyp. Based on familial clustering 
studies, it is estimated that 20-30% of CRCs have a potentially identifiable genetic 
cause(13).  
 
Figure 1: Frequencies of different types of CRC. 
In the European Union the incidence and mortality of CRC are 58/100 000 and 
30/100 000 per year, respectively. The American Cancer Society's most recent 
estimates for the number of colorectal cancer cases in the United States for 2011 
are: 101,700 new cases of colon cancer and 39,510 of rectal cancers with 49,380 
deaths. Risk factors according to the American Cancer Society for the development 
of CRC are: 
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a. Age: peak incidence in the 6Th/7Th decade. 
b. Nutrition: a diet that is high in red meat, processed meats and not enough fruits 
and vegetables consumption is a colon cancer risk. 
c. A family history of colorectal cancer: A family history of colorectal cancer or 
adenomatous polyps increase the risk of colorectal cancer. 
d. Member of certain racial or ethnic groups: African Americans get colon cancer 
more often than other racial groups in the U.S. and are nearly twice as likely to die 
from it. 
e. Inherited conditions such as familial adenomatous polyposis, which causes 
the development of 100-1000 of polyps in the colon, also raises the risk of colorectal 
cancer. 
f. Inflammatory bowel disease: such as ulcerative colitis and Crohn's disease (1).     
                                                             
Prognostication of newly diagnosed CRC predominantly relies on stage or anatomic 
extent of disease based on the International Union Against Cancer (UICC-TNM) (14) 
and American Joint Committee on Cancer (AJCC) (15) staging classifications. 
However, CRC should be regarded as a heterogeneous, multi-pathway disease, an 
observation substantiated by the fact that histologically identical tumours may have 
neither similar prognoses nor response to therapy (16). CRC progresses through a 
series of clinical and histopathological stages ranging from single crypt lesions 
through small benign tumors (adenomatous polyps) to malignant cancers 
(carcinomas). Stages are usually defined by TNM classification, where T describes 
the size of the tumor and whether it has invaded nearby tissue, N describes regional 
lymph nodes that are involved; M describes distant metastasis (spread of cancer 
from one body part to another). The depth of tumor invasion defines the T stage and 
increases from T1 (invasion of the submucosa) to T4 (invasion into the serosa or 
adjacent structures) (17). Grading considers the architectural arrangement and the 
differentiation grade of the neoplastic cells. Grade 1 is the most differentiated, with 
well-formed tubules and the least nuclear polymorphisms and mitoses. Grade 3 is the 
least differentiated, with only occasional glandular structures, pleomorphic cells and a 
high incidence of mitoses. Grade 2 is intermediate between Grades 1 and 3 (18).  
Colorectal cancer is thought to be initiated by inactivation of the adenomatous 
polyposis coli (APC) tumour-suppressor pathway in a cell somewhere within the 
colon. In ~85% of cases, the APC gene is mutated, whereas the β-catenin gene is 
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mutated in approximately half the remaining cases. The β-catenin protein is regulated 
by APC, and mutations in either gene have the same physiological effects. In few 
colorectal cancers without known mutations in APC or β-catenin, it is likely that other 
genes in the same pathway, or unusual mutations of APC or β-catenin, are to blame 
(12). The crypt in which the APC-mutant cell resides becomes dysplastic as 
abnormal cells accumulate to slowly produce a polyp. The development of a large 
polyp probably requires the acquisition of further mutations — for example, in the 
KRAS or BRAF oncogenes. Subsequently, 10–20% of these large polyps will 
progress to cancer by acquiring additional mutations in genes of the TGF-β pathway, 
the p53 pathway and other pathways that are still being actively researched. 
Individual cells within the bulk population that acquire such mutations are clonally 
selected on the basis of their improved fitness. This clonal selection creates a 
bottleneck in the development of the cancer, as mutations within this individual cell — 
advantageous and random — become fixed in future generations as its daughters 
overtake the rest of the cells in the tumour. Despite clonal selection, tumours are 
heterogeneous because of the continuing accrual of genetic changes. The whole 
process — from the occurrence of the first APC mutation to the development of a 
metastatic cancer — generally takes 20–40 years, and genetic instability develops at 
some point during this time (12). 
 
1.3 Etiology 
1.3.1 Genetic factors and family history 
CRC can be diveded into familial and sporadic cases, with sporadic cases accounting 
for the majority. Epidemiological studies have long indicated that the predisposition 
for CRC in the population may account for a substantial fraction of CRCs. First-
degree relatives of patients with sporadic CRC have been shown to have to three-
fold increased risk for both colorectal adenomas and CRC compared to the general 
population (19). 
 
1.3.2 High-risk familial CRC 
Several high-risk inherited forms of CRC syndromes are known and the predisposing 
genes have been characterized for the majority of the cases. These syndromes 
include familial adenomatous polyposis (FAP) and hereditary non-polyposis 
colorectal cancer (HNPCC). 
 11
1.3.3 Low-risk familial CRC 
Low-risk CRC families can be classified into two categories, two close relative (TCR) 
and one close relative (OCR). TCR refers to families having two affected first-degree 
relatives, and OCR refers to families having only one affected first-degree relative 
with an early age of tumor onset. TCR are in general MSI-negative. Epidemiological 
studies demonstrated that risk individuals in TCR and OCR damilies have a lifetime 
risk of CRC of 10-20% and 20-40%, respectively. (20). 
 
1.3.4 Non-genetic risk factors 
Epidemiological studies have recognized the contribution of non-genetic factors in 
the etiology of CRC for many years. Compelling evidence is given by the observation 
that, when Japanese have moved from their home country of low incidence to the 
USA of high incidence, their CRC risk increases to the same as that of their adopted 
country in 20-30 years. It should be pointed out the association of some dietary 
components (fiber, meat and fat) with CRC risk is still controversial, which requires 
large meta-analyses and prospective cohort studies in the future.  
 
1.4 Molecular aspects of CRC 
1.4.1 Genomic instability 
Most human malignacies are recognazed cytogenetically by marked aneuploidy and 
complex chromosomal rearrangements that include non-reciprocal translocations, 
DNA fragmentation and chromosome fusions (21). This chromosome instability (CIN) 
can be found in approximately 85% of CRCs. The remaining 15% of CRCs show a 
different genomic instability that is characterized by mismatch repair (MMR) 
deficiency. As this instability was first found in short repetitive DNA sequences known 
as microsatellites, it is named microsatellites instability (MSI, also known as MIN) 
(22). In addition, the third type of genomic instability, base excision repair (BER) 
instability, was identified recently to operate in a small proportion of CRCs (23).  
 
1.4.2 Chromosome instability (CIN)  
Polyploidy and aneuploidy are both frequent features of cancer cells (24). The 
chromosomal aberrations found in CRC are so complex that is too difficult to sum up 
all the chromosomal changes with a few representative karyotypes. The 
chromosomal instability — an accelerated rate of gains or losses of whole or large 
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portions of chromosomes (CIN) phenotype, which accounts for 85% of sporadic 
cases, exhibits gross chromosomal abnormalities such as aneuploidy and loss of 
heterozygosity (LOH) (12). Disruption of mitotic checkpoint assembly genes can lead 
to CIN because checkpoint defective cells can complete mitosis with inappropriately 
aligned chromosomes (12). Data strongly support the hypothesis that carcinogen 
exposure determines the type of instability in CIN cancers (7). Experimental evidence 
indicates that aneuploidy arises in cancers because of CIN. It refers to the rate with 
which whole chromosomes or large portions of chromosomes are gained or lost in 
cancers. Although it is believed that CIN is a process that drives most cancers to 
aneuploidy, the presence of aneuploidy per se does not imply the existence of CIN. 
There are several ways in which a cancer cell could become aneuploid in the 
absence of CIN. First, the cell could have gone through many more cell divisions than 
normal cells within a tissue, without a difference in the rate of chromosomal change 
per division. It is known that gross chromosomal changes occur in normal cells, so 
this possibility is a real one. Second, it is possible that the cancer cell was exposed to 
an endogenous or exogenous agent that induced aneuploidy, perhaps by interfering 
with proper spindle formation. The resultant daughter cells would be aneuploid, but 
not chromosomally unstable, in future generations. It is also possible that cancer cells 
develop chromosomal changes at the same rate as normal cells, but that gross 
chromosomal changes are lethal to the latter, but not the former. This possibility is 
consistent with the idea that oncogene and tumour-suppressor-gene mutations often 
seem to reduce apoptosis in the cancer cell. Although the ability to survive 
chromosomal changes might be scored as CIN in some assays, the mechanisms 
underlying this process would be very different. For example, mutations in genes that 
control the G2 checkpoint might result in CIN by stimulating chromosomal changes, 
whereas mutations in genes that control apoptosis would have no effect on the rate 
at which such changes occur if the rate in all cells was measured, rather than simply 
in surviving cells. CIN has only been formally shown for the gain or loss of whole or 
large portions of chromosomes in cancers. There is no assay at present that can 
reliably measure the rate of other chromosomal changes, such as rearrangements, 
deletions, insertions, inversions and amplifications .These latter changes are at least 
as common as losses or gains of whole chromosomes.  
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1.4.3 Microsatellite instability (MSI) 
The primary function of post-replicative mismatch repair (MMR) is to eliminate base-
base mismatches and insertion/deletions loops (IDLs) that arises as a consequent of 
DNA polymerase slippage during DNA synthesis (25, 26).  
The hallmark of MSI is widespread mutation of insertions and deletions in repetitive 
DNA sequences know as microsatellites. Microsatellites are scattered throughout the 
human genome and comprise tandemly repeated DNA sequences of 1-6 bases, most 
commonly as (CA)n, so are very prone to undergo slippage and replication errors in 
MMR-deficient cells (27). MSI was initially described in association with HNPCC (28) 
and soon found in 12-15% of sporadic CRCs (29). In addition, MSI is also detected in 
extra colonic cancers, such as gastric, breast, endometrial and upper urinary tract 
carcinomas (30, 31). The “mutator phenotype” conferred by MSI is beleved to 
contribute to the initiation and promotion of multistage carcinogenesis (32), but the 
simple inactivation of an MMR gene is not thought to be by itself a transforming 
event. There are many targets of MSI, especially those conteining repetitive 
sequences in the coding region. In 1995 TGFβRII was reported as the first target 
gene for instability in MSI tumors (33). Since then, many other important genes have 
been identified, including apoptosis –releted genes like BAX and Caspase-5 (34), the 
cell cycle regulator genes E2F4, TCF4 and PTEN (35, 36), the DNA repair genes 
hMSH3 and hMSH6 (37). In 1997, a National Cancer Institute (NCI) Workshop 
meeting held in Bethesda proposed a panel of five markers for the uniform detection 
of MSI tumors. This panel of markers includes two mononucleotides, BAT 25 and 
BAT 26, and three dinucleotide repeats, D2S123, D5S346 and D17S250 (38). 
Tumors with instability at two or more of these markers were defined as being MSI-
high (MSI-H), whereas those with instability at one repeat or showing no instability 
were defined as MSI-low (MSI-L) and microsatellite stable (MSS) tumors, 
respectively (38) (39). Dinucleotide markers are sensitive to MSI-L status, whereas 
mononucleotide are relatively specific for MSI-H cancers (40). 
The commonly used diagnostic MSI test based on polymerase chain reaction (PCR) 
sometimes produces unexpected and overlooked results, due to several reasons 
such as contamination of the tumor with normal cells and intralesional heterogeneity. 
(41). Another recently introduced rapid and not expensive technique to test MSI is 
immunohistochemistry (IHC) staining of the tumors (42). Tumors that have lost the 
function of one of the MMR genes show negative staining for the protein product of 
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that gene by IHC. In almost all evaluation studies using cases with already known 
MSI status and known pathogenic mutations, IHC always showed a concordant 
detection rate of more than 90% (41, 43, 44). It should be kept in mind that IHC 
cannot completely replace MSI analysis based on PCR as long as the role of other 
putative MMR genes in CRC will not be elucidated (45). MSI-H in HNPCC is caused 
by germline mutations in DNA MMR genes, hMSH2, hMLH1, hMSH6, and hPMS2 
(46, 47). MSI-H and MSI-L in sporadic CRCs are attributable to methylation and 
inactivation of the DNA repair genes hMLH1 and MGMT, respectively (39).  
 
1.4.4 Base-excision Repair (BER)  
The BER pathway plays a significant role in the repair of mutations caused by 
reactive oxygen species (ROS). These ROS can react with DNA to produce a variety 
of genotoxic lesions that have been implicated in many degenerative diseases such 
as aging, cancer, and neurodegenerative disorders. Three human BER components 
have been identified: OGG, MYH, and MTH; of these only the MYH gene has been 
demonstrated to have a pathogenic role in CRC development (23). CRCs with 
germline biallelic mutations in MYH contain an excess od G:C>T:A transversions in 
APC or KRAS in tumor cells tested, consistent with defective BER funtion (23, 48). 
 
1.5 Epigenetics 
Epigenenetic changes are modifications of the genome heritable during cell division 
that do not involve a change in DNA sequence (49). Since its discovery in 1983, the 
epigenetics of human cancer has been in the shadows of human cancer genetics. 
The genomic screening with a microarray-based strategy that combines gene 
expression status and epigenetic regulation has identified a large number of genes 
that are preferentially hypermethylated in CRC (50), substantiating the idea that 
epigenetic events play a key role in colorectal tumorogenesis. Global genomic 
hypomethylation at CpG dinucleotides is the first epigenetic abnormality identifies in 
cancer cells and involves every tumor type studied, both benign and malignant (49). 
It has been shown that hypomethylation occurs at an early stage in colorectal 
neoplasia (51). Hypomethylation can lead to gene activation by demethylating 
normally methylated CpG islands where genes reside. In addition, hypomethylation 
might favor mitotic recombination leading to LOH, as well as promoting karyotypically 
detectable rearrangement (52). CpG island are GC-and CpG areas of areas of 0.5 to 
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several Kb in size, usually located in the vicinity of genes and often found near the 
promoter of widely expressed genes (53). It has long ben recognized that CpG island 
hypermethylation plays a key role in silencing genes that are as critical for, and 
possibly as frequent in, tumorigenesis as mutations in coding regions. In sporadic 
CRC, it has been shown that the interruption of Ras signaling can be achieved by 
either genetic activation of the KRAS oncogene or epigenetic silencing of RAS 
effectors RASSF1 and RASSF2 (54, 55). Almost half of the tumor-suppressor genes 
that cause familial cancers through germline mutations can be inactivated through 
promoter hypermhetylation (56). In CRC, at least three predisposing genes for 
hereditary cases, MLH1, APC and LKB1, can undergo trascriptional inactivation by 
promoter hypermethylation in sporadic cases (57). Through the comparison of 
methylation profiles between MSI and MSS CRCs, a subset of colorectal tumors 
were shown to have a so-called CpG island methylator phenotype (CIMP), 
characterized by having higher incidence of hypermethylation at multiple promoter 
regions tested (58).  
 
1.6 Metastasis 
Most deaths in human cancer including CRC are due to metastatic disease that 
remains resistant to chemo-radiation-therapy (59). Metastasis consist of a series of 
sequential steps including shedding of cells from a primary tumor into the circulation, 
survival of the cells in the circulation, arrest in a new organ, extravasation into the 
surrounding tissue, initiation and maintenance of growth, and vascularization of the 
metastatic tumor (60). Despite the obvious importance of metastasis, the process 
remains incompletely characterized at the molecular and biochemical levels (61). It 
has long been recognized that certain tumor types tend to metastasize to specific 
organs. For example, breast cancer metastasizes to bone, liver, brain and lung while 
CRC preferentially spreads to liver (60).  
Metastatic cells are believed to be rare in the primary tumor mass that happen to 
acquire metastatic capability during late stages of tumor progression (62). However, 
recent expression profiling studies on human tumors reported that exist a gene 
expression signature strongly predictive of a short interval to distant metastases (63). 
Through comparing expression profiles of human primary tumors versus metastases, 
a common expression signature of only 17 genes was found to be associated with 
metastasis in different adenocarcinomas of various origin ( lung, breast, prostate, 
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colorectal, uterus, ovary) (64). An expression profiling study specific to CRC also 
identified a set of 194 known genes and 41 ESTs that discriminated well between 
samples with or without metastasis at dignosis or during follow-up (65). These 
studies suggested that a gene-expression program of metastasis may already be 
present in the bulk of some primary tumors at the time of diagnosis and could 
therefore be used to predict which tumors would become metastatic (64).  
 
1.7 Genetic alterations and tumorigenesis pathways 
Tumorigenesis is a multistep process, each step reflecting genetic alterations that 
drive the progressive transformation of normal human cells into highly malignant 
derivatives (2). The most of CRCs are believed to occur trough a well-know adenoma 
to carcinoma sequence identified almost three decades ago. In 1990, Fearon and 
Vogelstein proposed a stepwise genetic model of colorectal tumorogenesis (66). In 
this model, CRC was supposed to develop in a series of genetic alterations, 
corresponding with histological progression from normal colonic epithelium to 
adenomatous dysplasia through microinvasion, adenocarcinoma and, finally, 
metastasis. This model has been generally validated and some essential 
components of this model seem to occur in a predictable manner, such as APC, 
KRAS and p53. The APC gene, localized on chromosome 5q21, is an important 
component of the canonical Wnt/wingless trasduction pathway. Mutations in APC 
have been demonstrated in the majority of FAP patients in the germline (67) and in 
more than 80% of sporadic CRC, somatically (68).These mutations are thought to 
occur in the earliest stage in colorectal tumorigenesis, and precede the other 
alterations observed during CRC formation (69). It has been reported that even 
dysplastic aberrant foci, a presumptive precursor lesion to CRC, harbor APC 
mutation (70). In addition, LOH of 5q21 could be observed in at least 30% of colonic 
adenomas and adenocarcinoma, and it was presumed that APC was the most likely 
target of these events (69). Thus, APC inactivation appears to be the initial step in 
colorectal tumorigenesis. In this context, APC can be classified as a gatekeeper 
gene. 
 
KRAS, localized on chromosome 12p12, belongs, together with HRAS and NRAS, to 
a family of GTPases, which mediates cellular response to growth signals. In CRC, 
KRAS is the preferential target for genetic mutation compared with the other two 
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family members. Only a small percentage of CRCs have been reported to harbor 
mutations in N-RAS (71). KRAS is found mutated in approximately 50% of CRCs and 
a similar percentage of adenomas greater that 1cm in size, almost uniformly 
occurring as activating point mutations in codons 12, 13, and to a lesser extent, 61, 
as in other human tumors (69, 72). It has been noticed that small adenomas with 
APC mutations carry KRAS nutations in approximately 20% of tumors, whereas 
approximately 50% of more advanced adenomas have KRAS mutations (73), 
indicating KRAS mutations could promote clonal expansion during the early to 
advanced adenoma stage. However, KRAS mutations do not seem to initiate the 
tumorigenesis as APC mutations do. There have been several reports of KRAS 
mutations in histologically normal mucosa. In addition, it has been shown that KRAS 
mutations are not associeted with dysplasia (70). 
Mutation in p53 are the most common genetic alterations reported in a variety of 
human cancer. p53, as one of the crucial tumor suppressor genes in maintaining cell 
homeostasis, integrates numerous signaling pathways; however, the most important 
censequence of p53 inactivation in tumorigenesis is probably a complete loss of the 
DNA damage checkpoints in controlling cell cycle and apopthosis, leading to 
widespread genomic instability. In CRC, p53 mutations and allelic losses on 17p 
manifested as LOH are found in more than 75% of the tested cases (69). 
Furthemore, mutation of p53 coupled with LOH of 17p was found to coincide with the 
appearance of carcinoma in an adenoma, pointing out to its role for malignant 
transformation as a late event (74). 
 
1.8 Serrated pathway 
Two distinct molecular pathways underlie most CRCs. Approximately 70% arise from 
the way of the well know and characterized chromosomal instability pathway. Over 
the last two decades, many of the molecular mechanisms of the “serrated neoplasia 
pathway”, so called for the pattern of crypts in the precursor polyps, accounting for 
approximately 30% of CRCs have been determined (75). In 1980 the only recognized 
serrated polyps were considered non-neoplastic lesion (76) but today the “serrated 
neoplastic pathway” describes the progression of serrated polyps to CRC (Figure 2). 
Early reports defined the molecular features of the serrated neoplasia pathway: (i) 
MAPK (Mitogen-Activated Protein Kinase) pathway activation, involving KRAS and 
BRAF; and (ii) CIMP (CpG island methylator phenotype). Currently, three major 
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categories of serrated polyp are recognized in the World Health Organization (WHO) 
classification: hyperplastic polyps (HP) sessile serrated adenoma/polyp (SSA) and 
traditional serrated adenomas (TSA). In 2007, Jass proposed three broad molecular 
profiles for serrated pathway carcinoma which have been modified as follow:  
1. BRAF mutant, CIMP-H; with (a) MSI-H, or (b) MSS. 
2. KRAS mutant, CIMP-L, MSS. 
The group 1 is the most strongly linked with serrated neoplasia pathway compared to 
the group 2.  
 
Figure 2 : Serrated, Familial and Conventional pathways to colorectal cancer. 
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1.9 The angiogenic vascular system 
1.9.1 The vascular endothelial growth factor family and its receptors 
In the developing embryo, initial blood vessels appear through a process known as 
vasculogenesis, in which blood vessels form de novo by differentiation and 
coalescence of individual progenitor cells (77). These progenitors are mesoderm-
derived and can generate only endothelial cells (angioblasts) in response to vascular 
endothelial growth factor (VEGF), or can differentiate both in endothelial and 
hematopoietic cells (hemangioblasts) (78). After commitment to the endothelial 
lineage, angioblasts generate specialized structures, called blood islands, which can 
then fuse and remodel in response to haemodynamic forces to generate the first 
primitive plexus of vessels (78). Later in development, during differentiation, 
endothelial cells in the plexus become committed to either arterial or venous fate (78) 
(Figure 3).  
 
Figure 3: Representative pictures of the vessels development and differentiation. 
 
Recent studies identified several signaling pathways controlling arterial and venous 
identities of endothelial cells, such as the complex Eph-Ephrin system. In addition, 
VEGF, Notch, angiopoietins, platelet derived growth factor (PDGF) and transforming 
growth factor (TGF)--beta are also key molecular determinants of vascular 
morphogenesis both in embryo and in adults (79). 
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After endothelial cell specification, the vascular plexus expands giving rise to a 
functional network of vessels by sprouting. After the formation of the immature 
plexus, mural cells that interact with the outer surface of the vessel are recruited 
(Figure 3). Most often, these cells are pericytes and invest the vast majority of 
capillary-size vessels in the body. Smooth muscle cells indeed cover large vessels, 
such as arteries and veins. During adult life, neovascularization occurs predominantly 
through angiogenesis, the growth of blood vessels from pre-existing capillaries. Blood 
vessel formation by angiogenesis is an extremely complex multistep process, which 
requires the tight control and coordination of endothelial cell behavior in all its phases 
(79). 
The generation of new capillaries from pre-existing ones can be represented as a 
process in two phases: 1) tube formation, in which endothelial cells react to growth 
factor gradients and local concentration, migrating, proliferating and generating the 
new sprout and 2) vascular maturation, in which the nascent vessels are then 
stabilized by recruiting mural cells (pericytes or vascular smooth muscle cells) and by 
generating extracellular matrix (ECM) (80). Pericytes play a crucial role in regulating 
the physiology of the microvasculature. Their association with the newly-induced 
vessels render them independent of VEGF stimulus, whereas vessels lacking 
perictyes tend to regress following VEGF withdrawal (80). 
In adult life, neovascularization is not only due to angiogenesis. Recent studies 
revealed that postnatal vasculogenesis can occur through the recruitment of 
endothelial progenitors cells (EPC) circulating in peripheral blood (81). These cells 
can be recruited at the site of revascularization and incorporated within the forming 
vasculature in distant organs in various disorders, such as hypoxic conditions or 
tumors (81). Most of these circulating EPCs reside in the bone marrow and can be 
mobilized in response to various stimuli including VEGF, GM--CSF, FGF--2 and 
angiopoietins (82). In addition, it has been reported that bone marrow derived 
-macrophages can also contribute to neovascularization by in situ trans-
differentiation to endothelial cells (83). Recently, another population of recruited 
bone--marrow circulating cells (RBCCs) has been described. These cells do not 
function as EPC but contribute to neovessel formation. Their homing and retention in 
close proximity of angiogenic vessels is mediated by VEGF and SDF1, a chemokine 
induced by VEGF. These cells are able to enhance in situ proliferation of resident 
endothelial cells and therefore to promote adult neovascularization (84). 
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1.9.2 Molecular regulation of angiogenesis 
The first suggestion of the existence of angiogenic factors comes from the pioneering 
work of Gordon Ide and collaborators in the early 20th century. Using a transparent 
chamber inserted into the rabbit ear as a model of tumor transplantation, they 
observed that tumor growth was accompanied by a strong angiogenic response (85). 
This observation led them to postulate for the first time that tumor cells released 
growth factors able to induce vessels growth. Subsequently, several other studies 
contributed to the discovery and characterization of numerous angiogenic factors 
such as VEGF, angiopoietins, TGF--β, fibroblast growth factor (FGF), hepatocyte 
growth factor (HGF) (86). Among them, VEGF is the most potent and specific 
angiogenic factor. In 1989, it was isolated for the first time from medium conditioned 
by bovine pituitary follicular cells as specific endothelial cell mitogen (87). At the 
same time, other research groups reported the identification of a protein that induced 
vascular leakage that was named tumor vascular permeability factor (VPF) (88) and 
isolated an endothelial mitogen from mouse pituitary cell line called “vasculotropin”. 
Later on, cloning and sequencing of those molecules revealed that VEGF and VPF 
was the same molecule whereas vasculotropin was the mouse orthologue of VEGF 
(89).  
The mammalian Vascular Endothelial Growth Factor (VEGF) family is the best 
characterized and includes five members: VEGF-A, -B, -C, -D (also known as FIGF) 
and placenta growth factor (PIGF). In addition, ORF viruses (an epitheliotropic DNA 
parapoxvirus) can produce a VEGF homologue called VEGF-E.  
Currently, three main subtypes of VEGF receptor tyrosine kinases have been 
described: VEGFR-1, VEGFR-2, and VEGFR-3. All of them are defined by seven 
immunoglobulin homology domains in the extracellular tyrosine kinase domain. 
VEGFs are secreted as dimers, the binding to their receptors leads to dimerization 
and trans-autophosphorylation of VEGFRs.  
VEGF-A represent the best-studied VEGF family members (commonly referred to as 
VEGF). It has been described as a glycosylated mitogen protein that specifically acts 
on endothelial cells and has various effects, including increased vascular 
permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, 
promoting cell migration, and inhibiting apoptosis in both physiological and 
pathological conditions. It is expressed as various isoforms owing to alternative 
splicing that leads to mature 121-, 165-, 189- and 206-amino-acid proteins, although 
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proteolytic cleavage of these isoforms can lead to other, smaller isoforms. VEGF165 
is the predominant isoform, commonly overexpressed in a variety of human solid 
tumours. As its name implies, VEGF-A activity has been studied mostly on cells of 
the vascular endothelium, although it acts on a number of other cell types (e.g., 
stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial 
cells).  
Inherent or acquired resistance to anti-VEGF therapy is frequently observed in 
tumors, thus illustrating the need for targeting additional angiogenesis pathways to 
fully exploit the promise of anti-angiogenic cancer therapy. Notch signaling has 
recently emerged as a critical regulator of developmental and tumor angiogenesis. 
Notch signaling in both endothelial and smooth muscle cells appears to provide 
critical regulatory information to these cells downstream of the initiating signal 
induced by VEGF (90).  
The Notch pathway is an evolutionary conserved signaling system that regulates cell 
fate specification, tissue patterning and morphogenesis by modulating cell 
differentiation, proliferation, apoptosis and survival (91). The Notch gene, first 
characterized in Drosophila melanogaster, encodes a 300-kD single-pass trans-
membrane receptor (91). Functional studies in mice, zebrafish and cultured 
endothelial cells have demonstrated a critical role for Notch signaling during 
formation of the vascular system (90). Of the four Notch receptors, Notch1 and 
Notch4 are expressed by endothelial cells (92). Gene targeting studies in mice have 
demonstrated that Notch1 is the primary functional Notch receptor during 
developmental angiogenesis (90). Except for Dll3, expression of all Notch ligands has 
been detected in endothelial cells. Dll4 is the first Notch ligand to be expressed 
during mouse development, and Dll4 transcripts were detected in most capillary beds 
and arterial vessels (90). Lack of a single Dll4 allele in mice leads to early embryonic 
lethality characterized by severe defects in arterial differentiation and vascular 
remodeling (93). 
The best characterized consist of vessels sprouting, relies on a balanced formation of 
tip cells, which migrate towards the VEGF gradient, and stalk cells, which instead 
proliferate behind the tip. These initial morphogenic events require the generation of 
an alternate pattern of Dll4 expression on tip cells and consequent Notch1 activation 
on neighboring endothelial cells, which become stalk.  
 23
VEGFA mediated tumor-induced angiogenesis has been reported to be a critical step 
in both tumor growth and metastasis formation (94). Concerning CRC, to date the 
majority of studies using either immunohistochemistry (IHC) for the detection of 
VEGFA protein in tumor tissue, mRNA or soluble plasma VEGFA levels all point 
towards a significant negative prognostic survival effect of increased VEGFA 
expression. On the other hand, VEGFC (Vascular endothelial growth factor C) 
mediated tumor-induced lymph/angiogenesis plays an important role in regional 
lymph nodes metastasis formation (95). VEGFC has been described as the main pro- 
lymphangiogenic factor (95). VEGFC can induce lymphatic endothelial cell 
proliferation and migration as well as vascular permeability (96). Angiogenesis has 
been demonstrated to be a landmark step for tumor disease progression, on one 
hand sustaining primary tumor growth and on the other promoting distant metastasis 
formation. Thus considering the importance of angiogenesis regulation in cancer 
progression, several anti-angiogenic agents have been developed in the last few 
years. Initially, results in preclinical models clearly demonstrated tumor response to 
anti-VEGFA therapy in terms of tumor shrinkage and metastatic incidence reduction. 
However, more recent data reported that a number of tumors although initially 
responding to VEGFA inhibition become resistant at later stages of treatment (97).  
 
1.9.3 Anti-angiogenic therapy : Bevacizumab 
In human patients, in last years the main anti-angiogeninc therapeutic agent brought 
into the clinic has been Bevacizumab® (BV) (Roche; Figure 4). 
 
Figure 4: Avastin (Bevacizumab) San Francisco, Calif. Genetech, Inc; 2004. 
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In 1997, Ferrara et al. reported the humanization of the murine anti-VEGF 
monoclonal antibody A.4.6.1. Like its murine counter-part, BV binds to and 
neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, but not 
mouse or rat VEGF; it prevents VEGFA binding to the VEGF receptors (VEGF-R1 
and VEGF-R2) mainly expressed on endothelial cells, thus inhibiting angiogenesis 
and inducing normalization of immature and abnormal blood vessels (98). In addition, 
the VEGF-R2 has been found to be expressed in CRC cells in about 50 % of 
published studied (99). Since 2004 in the United States, BV has been approved in 
addition to first line-therapy for mCRC patients’ treatment. BV administration as 
single therapeutic agent has not shown significant anti-tumoral activity. However, if 
combined with IFL (irotencan/5FU/leucovorin) or FOLFOX 
(oxaliplatin/5FU/leucovorin), BV results in better tumor response rates and enhanced 
patients’ progression free-survival (100, 101). Furthermore, BV has been also 
approved as second line therapeutic agent for irinotecan-refractory mCRC patients. 
In combination with FOLFOX it results in patients overall survival (OS) increase up to 
12.5 months compared to 10.7 months in the control only FOLFOX treated arm (102). 
Nevertheless, despite BV use beneficial effects in CRC affected patients’, it has to be 
considered that such a therapy produces only marginal OS improvement despite its 
considerable additional cost. Moreover, even if BV is generally well tolerated, without 
increasing the chemotherapy toxicity, its administration presents some dangerous 
and possibly fatal adverse effects. Notably, thrombo-embolic complications (2.4% 
incidence compared to 0.7% in the control arms), gastro-intestinal perforation 
(between 0.3 to 2.4% across clinical studies) and slower or incomplete wound 
healing (15% of treated patients) have been observed (103). Finally, the occurrence 
of anti-angiogenic therapy resistance, possibly explaining the poor OS benefits in BV 
treated mCRC patients, suggests that this therapeutic approach needs appropriate 
diagnostic tools in order to optimize its efficacy. Among the possible key players 
mediating anti-angiogenic therapy resistance, recently DLL4-Notch signalling has 
gained a great deal of interest. DLL4, one of the Notch ligands, has been found up 
regulated in a variety of human cancers and in CRC as well (90). When the ligand 
DLL4 binds to its receptor Notch, these results in the release of the Notch 
intracellular domain (named NICD). NICD goes to the nucleus where it functions as a 
transcriptional regulation of targets genes as Hes1, Hey1, and EprinB2. Notably it 
has been shown that Notch can directly inhibit angiogenesis via regulating the 
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number of endothelial tip cells therefore controlling the angiogenic sprouting 
processes (90). DLL4 over-expression in tumor models has been shown to reduce 
the overall vessels number but on the other hand to increase the vascular lumen 
size.  In a randomised phase III trial, where breast cancer patients were treated with 
combination of capecitabine and BV, low DLL4 tumor expressing patients had a 
significant prolongation of PFS compared to high DLL4 tumor expressing patients 
(90). Furthermore, in a pre-clinical glioma xenograph model over expressing DLL4, 
tumors were found to be insensitive to BV treatment (104), thus corroborating clinical 
results. Most importantly, it has been demonstrated that large vessels rather than 
small capillaries play a major role in the BV resistance. It is known that BV play its 
major effect on small vessels regression, but has virtually no effect on bigger size 
stabilized vessels that are less depended to VEGF stimuli. A number of other 
pathways and molecules such as FGF2/FGFR, VEGF-C/VEGFR3 axes, EphrinB4 
and EphB4, have been involved in the occurrence of anti-angiogenic resistance, 
however  the global picture of this phenomenon is overall still unclear.  
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2. Aim of the study 
The aims of this study was to assess the presence of VEGFA genomic alterations in 
colorectal cancer (CRC) and clarify how these genomic alterations can modulate 
CRC patients’ response to BV treatment in addition to first line therapy (5fluorouracil, 
leucovorin, capecitabine, oxaliplatin, mephedrone). Among our goals we aim to find 
out predictive biomarkers to improve anti-angiogenic therapy efficacy and possibly to 
develop new therapeutic approaches by setting out new rational drug combinations. 
Of importance, this study allowed us to contribute to the improving patient’s treatment 
efficiency as well as reducing the economic cost of ineffective therapy. To conclude, 
we believe that CRC patients will greatly benefit from our research activities. 
Altogether, our study helped the setting of personalized therapeutic strategies by: i) 
identifying those patients who really will profit of BV treatment, ii) sparing 
unnecessary side effects and costs for the non-responder CRC patients especially 
and iii) planning future alternative and/or combination treatments for CRC patients 
based on the functional results. 
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Chapter I 
VEGFA gene locus (6p12) amplification identifies a small but highly aggressive 
subgroup of colorectal patients. 
1.1 Patients 
1.1.1 Cohort 1 
 A first cohort of 1420 patients with primary colorectal cancer diagnosed at the 
Institute of Pathology, University Hospital Basel, Institute of Clinical Pathology, Basel 
and the Triemli Stadtspital were entered into this study. Histomorphological and 
clinical information included age at diagnosis, tumor diameter, gender, tumor 
location, histological subtype, pT classification, pN classification, tumor grade, 
vascular invasion, mismatch repair status and survival time information. Information 
on postoperative therapy, distant metastasis and local recurrence were retrieved from 
patient records and available in 1/3 of the cases. Censored observations included 
patients who were alive at the last follow-up, died for reasons other than colorectal 
cancer or were lost to follow-up. 
1.1.2 Cohort 2 
 A second cohort of 221 nonconsecutive patients treated at the 4th Department of 
Surgery, University of Athens Medical School, randomly selected from the archives of 
the 2nd Department of Pathology, University of Athens Medical School (Attikon 
University Hospital), Greece, were entered into this study. Patients were treated 
between 2004 and 2006. All histomorphological data were reviewed from the 
corresponding hematoxylin and eosin (H&E)-stained slides, whereas clinical data 
were obtained from corresponding reports. Clinicopathological information for all 
patients included age, tumor diameter, gender histological subtype, tumor location, 
pT stage, pN stage, pM stage, tumor grade, vascular invasion, lymphatic invasion 
and mismatch repair status. Information on postoperative therapy and follow-up time 
was available for all patients. 
1.2 Specimens 
The use of material was approved by the local ethics committees of the University 
Hospital of Basel and University of Athens, respectively. 
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1.2.1 Tissue microarrays 
Paraffin-embedded tissue blocks from all patients in both cohorts 1 and 2 were 
retrieved and two tissue microarrays were constructed. For cohort 1, a single-punch 
tissue microarray consisting of 1420 colorectal cancer specimens and 57 normal 
mucosa samples was established. In cohort 2, in order to exclude bias due to 
possible tumor heterogeneity, each patient had multiple tissue and tumor punches 
taken from formalin-fixed, paraffin-embedded blocks using a tissue cylinder with a 
diameter of 0.6 mm that were subsequently transferred into one recipient paraffin 
block (3 × 2.5 cm) using a homemade semiautomated tissue arrayer. Tissues were 
obtained from the tumor center, the invasive tumor front, the normal adjacent mucosa 
(if available), and the transitional zone where tumor and normal adjacent mucosa first 
interact (if available). Each patient on average had 5.1 tissue punches included on 
this array with an average of four tumor punches. The final tissue microarray 
contained 1079 tissues: namely, 437 tissues from the tumor center, 430 from the 
invasive front, 90 from normal adjacent mucosa and 122 from the transitional zone. 
1.2.2 Whole tissue sections 
Additionally, in order to assess the intratumoral heterogeneity of VEGFA 
amplification, 25 whole tissue sections from patients with metastatic colorectal cancer 
treated between 2003 and 2010 at the University Hospital Basel were selected from 
the archives of the Institute for Pathology. 
1.3 Assay Methods 
1.3.1 FISH (cohorts 1 and 2 and whole tissue sections) 
Tissue microarray and whole tissue sections were used for dual-labelling FISH. The 
genomic BAC clone RPCIB753M0921Q (imaGENES GmbH, Berlin, Germany), which 
covers the VEGFA gene region, was used for preparation of the FISH probe. A 
starter culture of 2–5 ml LB medium was inoculated with the BAC clone and 0.5 ml of 
the starter culture was diluted in 500 ml selective LB medium. BAC-DNA was isolated 
using the Large-Construct Kit (Qiagen, Hombrechtikon, Switzerland) according to the 
instructions of the manufacturer. BAC identity was verified by sequencing using 1 µg 
of isolated DNA and 20 pmol of SP6, respectively, T7 primers (EuroFins MGW 
Operon, Ebersberg, Germany). Isolated BAC-DNA (1 µg) was digested with AluI 
restriction enzyme (Invitrogen, Lucerne, Switzerland) and labelled with Cy3-dUTP 
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(GE Healthcare, Buckinghamshire, UK) using the BioPrime Array CGH Kit 
(Invitrogen). Labelling reaction was assessed by usage of a Nanodrop assay 
(Nanodrop, Wilmington, DE, USA). The labelled DNA was purified by using the FISH 
Tag DNA Kit (Invitrogen). Tissue microarrays and whole tissue sections were 
subjected to pretreatment as previously described (105). FISH probe was applied 
and after a denaturation step (10 min at 75 °C), the slides were incubated overnight 
at 37 °C. Washing of the slides was performed with the Wash Buffer (2 × SSC, 0.3% 
NP40, pH 7–7.5) and slides were counterstained with DAPI I solution (1000 ng/ml; 
Vysis Abbott Molecular, Abbott Park, IL, USA). As reference, a Spectrum Green-
labelled chromosome 6 centromeric probe (Vysis Abbott Molecular) was used. 
Images were obtained by usage of a Zeiss fluorescence microscope using a 63 × 
objective (ZEISS, Feldbach, Switzerland) and the Axiovision software (ZEISS). 
1.3.2 Immunohistochemistry (cohort 1) 
Immunohistochemistry was performed on the tissue microarray for protein markers p-
MAPK3/MAPK1 (clone 20G11, dilution 1:100; Cell Signaling Technology, Danvers, 
MA, USA), RAF-1 kinase inhibitor protein (PEBP1; dilution 1:1000; Upstate, New 
York, NY, USA), receptor for hyaluronic acid-mediated motility (HMMR (RHAMM); 
clone 2D6; dilution 1:25, Novocastra, Newcastle, UK), T-cell-originated protein kinase 
(PBK; PBK/TOPK, rabbit polyclonal, dilution 1:50, Cell Signaling Technology), p-AKT 
(clone 244F9, dilution 1:00; Cell Signaling Technology), urokinase plasminogen 
activator (PLAU; no. 3689; dilution 1:25; American Diagnostica, Stamford, CT, USA) 
and its receptor (PLAUR, no. 3936; dilution 1:25; American Diagnostica) as well as 
for TP53 (DO-7; Dako Cytomation, Glostrup, Denmark) and VEGFA (polyclonal; 
1:300; Santa Cruz, CA USA). Cutoff scores for ‘overexpression/positivity’ compared 
with ‘loss/negativity’ were previously established and determined to be: 70% for 
PEBP1, 90% for HMMR (RHAMM), 0% for pMAPK3/MAPK1, 0% for p-AKT, 90% for 
PBK, 60% for PLAU, 75% for PLAUR and 90% for VEGFA. 
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1.4 Results 
1.4.1 Cohort 1 
Frequency of VEGFA amplification and association with clinicopathological 
parameters 
FISH analysis of the VEGFA gene locus was evaluable in 1280 of 1420 (90%) 
colorectal cancer punches. Amplification was found in 39/1280 (3%; Figure 5). 
Amplified tumors were more frequently of larger diameter (P=0.045), right sided 
(P=0.016) and were of higher pT stage (P=0.022), higher tumor grade (P=0.024) and 
had vascular invasion (P=0.003; see paper below Table 1). No particular pattern of 
tumor recurrence was observed. VEGFA amplification was significantly linked to 
unfavorable prognosis with 5-year disease-specific survival rates of 31% (95% CI 17–
46) compared with 57.1% (95% CI 54–60) for not-amplified cases (P<0.001; Figure 
6a). Taking into account the number of patient deaths in the amplified group 
(n=27/37; 1 patient had no survival time information), multivariable survival time 
analysis was performed to determine the effect of VEGFA amplification when 
adjusting for pN stage and vascular invasion. Despite the small number of amplified 
cases, the highly negative impact of VEGFA gene locus amplification on survival time 
was maintained (HR 2.09; 95% CI 1.4–3.1; P<0.001) when controlling for the effects 
of pN stage (HR 2.58; 95% CI 2.1–3.1; P<0.001) and vascular invasion (HR 2.17; 
95% CI 1.8–2.6; P<0.001). 
     
Figure 5: Fluorescence in situ hybridization (FITC+Rhodamine+DAPI) of the VEGFA 
gene locus 6p12 in colorectal cancer. (a) Negative case with no amplification. (b) 
Amplified colorectal cancer. 
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 Figure 6: Kaplan–Meier survival curves showing the highly negative prognostic effect 
of VEGFA gene locus amplification in (a) cohort 1 and (b) cohort 2. 
1.4.2 Cohort 2 
Validation of VEGFA and association with clinicopathological parameters and 
prognosis 
 Using a second external validation cohort of 221 patients, FISH analysis of the 
VEGFA gene locus was evaluable in 195 colorectal cancers of which 11/195 (5%) 
showed gene amplification. Trends toward a more frequent higher tumor grade 
(P=0.016), vascular (P=0.032) and lymphatic invasion (P=0.008) were observed in 
patients with amplified tumors (see paper below Table 2). Of the 11 patients with 
VEGFA amplification, 7 (63%) died of disease compared with 61/175 (35%) of 
nonamplified cases. Moreover, a trend for negative prognostic impact was observed 
for patients with VEGFA amplification compared with not-amplified cases, particularly 
at earlier time points (P=0.009; Figure 6b). No multivariable analysis could be 
performed for this small-amplified subgroup. 
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Chapter II 
VEGFA gene locus analysis across 80 human tumour types reveals gene 
amplification in several neoplastic entities. 
2.1 Materials and methods 
2.1.1 Tissue microarrays 
A pre-existing set of six TMAs with 3,417 tissue samples from 80 tumour entities and 
31 normal tissue types was used in this study (106, 107). All tissue samples were 
retrieved from the archives of the Institute of Pathology (University of Basel, 
Switzerland) and were reviewed by experienced pathologists (L.T. and L.M.T.). 
Briefly, to construct the TMAs, tissue samples were fixed in buffered 4 % formalin 
and embedded in paraffin. H&E-stained sections were made from each selected 
primary block (named donor blocks) to define representative tissue regions. Tissue 
cylinders (0.6 mm in diameter) were then punched from the region of the donor block 
with the use of a custom-made precision instrument (Beecher Instruments, Silver 
Spring, USA). Afterwards, tissue cylinders were transferred to a 25 × 35 mm paraffin 
block to produce the TMAs. The resulting TMA block was cut into 3-µm sections that 
were transferred to glass slides by use of the paraffin sectioning aid system 
(Instrumedics, Hackensack, USA). Sections from the TMA blocks were used for FISH 
analysis. The use of the clinical samples from the biobank of the Institute of 
Pathology for the TMA construction was approved by the Ethics Committee of the 
University Hospital of Basel (EKBB). In addition, we used a second set of three TMAs 
comprising a total of 194 tissue samples obtained from 24 different human tumour-
derived xenograft types in nude mice models (Oncotest GmbH, Freiburg, Germany). 
2.1.2 Preparation of FISH probe 
The genomic BAC clone RPCIB753M0921Q (imaGENES GmbH, Berlin, Germany), 
which covers the VEGFA genomic region (6p12) was used for preparation of the 
FISH probe. A starter culture of 2–5 ml LB medium was inoculated with the BAC 
clone and 0.5 ml of the starter culture was diluted in 500 ml selective LB medium. 
BAC-DNA was isolated using the Large-Construct Kit (Qiagen, Hombrechtikon, 
Switzerland) according to the manufacturer’s instructions. BAC identity was verified 
by sequencing using 1 µg of isolated DNA and 20 pmol of SP6, using T7 primers 
(EuroFins MGW Operon, Ebersberg, Germany). 1 µg of isolated BAC-DNA was 
 34
digested with Alu I restriction enzyme (Invitrogen, Lucerne, Switzerland) and labelled 
with Cy3-dUTP (GE Healthcare, Buckinghamshire, UK) using the BioPrime Array 
CGH Kit (Invitrogen, Lucerne, Switzerland). Labeling reaction was assessed by 
usage of a Nanodrop assay (Nanodrop, Wilmington, USA). The labelled DNA was 
purified by using the FISH Tag DNA Kit (Invitrogen, Lucerne, Switzerland). 
2.1.3 FISH analysis 
TMAs were subjected to pre-treatment as previously described (105). FISH probe 
was applied and after a denaturation step (10 min at 75 °C), the slides were 
incubated over night at 37 °C. Slides were afterward washed with washing buffer (2X 
SSC, 0.3 % NP40, pH 7–7.5) and slides were counterstained with DAPI I solution 
(1,000 ng/ml) (Vysis Inc. Abbott Molecular, Abbott Park, USA). As reference, a 
Spectrum Green-labelled Chr6 centromeric probe (CEP6) (Vysis Inc. Abbott 
Molecolar, Abbott Park, USA) was used. Images were obtained by usage of a Zeiss 
fluorescence microscope using a 63X objective (ZEISS, Feldbach, Switzerland) and 
the Axiovision software (ZEISS, Feldbach, Switzerland). Two expert pathologists 
counted a minimum of 100 tumour nuclei signals in four separate regions of the 
tissue section independently; consensus on non-matching results was achieved. 
FISH results were interpreted according to: (1) absolute Chr6 copy number or (2) the 
ratio VEGFA gene/Chr6 copy number. We classified as not amplified samples with a 
VEGFA/Chr6 ratio of <1.8; equivocal/borderline with a VEGFA/Chr6 ratio between 
1.8 and 2.2, amplified with a VEGFA/Chr6 ratio higher than 2.2, as proposed by the 
ASCO/CAP guidelines for HER2 amplification in breast cancer (108). Polysomy of 
Chr6 was defined as an average of the Chr6 copy number. When the average was 
included between 2.26 and 3.75, the polysomy 6 was defined as low whereas, when 
the average was >3.75 the polysomy 6 was defined high (109-112). In addition, we 
have further categorized the amplified samples using a second selection criterion 
(referred in the tables as: alternative cut off criterion) discriminating between high (i.e. 
>10 VEGFA/Chr6), average (5–10 VEGFA/Chr6) or low number of gene copies. 
2.2 Micro-vessel density (MVD) quantification 
To evaluate micro-vessel density MVD, CD31 Ab (Ventana, Cat. Num: 760-4378; 
pre-diluted) was used as marker of blood vessels. Immunostaining was performed 
using Benchmark® XT system (Ventana) according to the manufacturer’s guidelines. 
 35
MVD was assessed on a small cohort of CRCs (total n = 10, not amplified n = 3, 
polysomic n = 4, amplified n = 3). Staining evaluation and vessel counting (number of 
vessel per field—0.74 mm2) were performed by two expert pathologists in a blinded 
manner (L.T. and L.M.T.). 
2.3 Xenograft mouse 
Human derived tumour tissue was cut into pieces of 4–5 mm edge length. For 
implantation 4–6 week old homozygous nude mice were used. Briefly, once mice 
were fully anesthetized, the skin and sub cutis were carefully separated by using 
scissors in order to form a “subcutaneous pocket” on the animal’s flank, where one 
tumour fragment per side was placed. After equipping the animal with a unique 
identification tag (ear tag or transponder), the animal was disinfected and put to fresh 
cage for recovery from the anaesthesia. Afterwards, tumours growing 
subcutaneously in nude mice were explanted and prepared by removal of visible 
necrotic areas, large blood vessels and surrounding mouse tissue (pseudo-capsule). 
Immediately after, samples were snap frozen in liquid nitrogen and stored at −80 °C. 
Additional tissues were collected for TMAs preparation. 
2.4 DNA preparation 
DNA was extracted from snap frozen tumour xenografts. Tumours were digested with 
proteinase K at 55 °C overnight and the lysate treated with DNAse-free RNAse 
(Qiagen, Hombrechtikon, Switzerland). DNA was extracted by 
phenol:chloroform:isoamylalcohol and precipitated by ethanol. DNA pellets were then 
washed and resuspended in TElow. The integrity of each DNA preparation was 
checked on a 1.3 % agarose gel and the purity analysed using NanoDrop 2000 
(Thermo Scientific, Canada). 
2.5 CGH array profiling 
DNA was hybridized to 244 K whole-genome Agilent arrays at Shangai Biochip Ltd, 
China, according standard internal procedure. In brief, 1.5 µg of DNA were 
fragmented by a double enzymatic digestion (AluI + RsaI) for 2 h at 37 °C followed by 
enzymes inactivation at 95 °C. Digested DNA checked on a 0.8 % agarose gel prior 
to labelling and hybridization. Digested DNA were labelled by random priming with 
CY5-dCTPs and CY3-dCTP, respectively, and hybridized at 65 °C for 40 h. The chips 
were scanned on an Agilent Scanner and image analysis was done using the 
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Feature-Extraction V10.7.3.1 software (Agilent Technologies). Feature-Extraction 
was used for the fluorescence signal acquisition from the scans. Normalization was 
done using the ranking-mode method available in the Feature-Extraction V10.7.3.1 
software. 
2.6 Data analysis 
FISH data were summarized into tables and relative percentage of gene amplification 
as well as chromosomal polysomy were calculated for each tumour. Concerning 
CGH results, array data were analysed and processed with R (113) and the 
Bioconductor software framework (114), using the snapCGH package (115) for 
normalization, as well as custom routines for data processing and visualizations. 
Segmentation for subsequent calling of chromosomal aberrations was done using the 
circular binary segmentation algorithm (116) already implemented in the 
Bioconductor package DNAcopy (117). 
2.7 Results 
2.7.1 VEGFA locus amplification is observed in a large subset of tumour types 
In order to investigate the incidence of VEGFA gene locus amplification across 
several tumour types, we took advantage of a FISH VEGFA specific probe to screen 
a set of multi-tumour TMAs. Out of the 3,417 tissue samples composing our set of 
tissues (including 315 normal specimens as controls) and representing 80 different 
tumour entities, 2,837 were evaluable by FISH. Causes of exclusion were either the 
absence of tissue punch or poor hybridization quality. 
Our analysis revealed VEGFA amplification in 10 different tumour types with 
prevalence rates between 1.5 % and 5 % (Table 1 and Table 2 for complete list). 
Representative pictures of amplified samples as detected using FISH are shown in 
Fig. 7. Since an increased gene copy number can also be caused by polysomy 
instead of focal amplification, we further investigated the polysomic status of Chr6, as 
defined by Ma et al. (112). We observed polysomy of Chr6 in 18 of the 80 analysed 
tumour types (Table 3 and Table 4). In addition, we have further categorized the 
amplified samples using another selection criterion discriminating between high (i.e. 
>10 VEGFA/Chr6), average (5–10 VEGFA/Chr6) or low number of gene copies 
(Table 5 and Table 6). Some tumours such as gallbladder adenocarcinoma, 
squamous cell carcinoma of the larynx, ovary (both serous and endometrioid 
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carcinoma subtypes) and stomach adenocarcinoma of intestinal type showed both 
amplified and polysomic cases with serous endometrium carcinoma and large cell 
lung carcinoma having the highest incidence of 16 and 10 % of cases, respectively. 
Of note, in our investigation none of the breast cancer samples from either ductal 
(n = 30), medullary (n = 50) or mucinous (n = 16) subtypes were found to feature 
VEGFA focal amplification, conversely polysomy was observed in all of them, with an 
incidence of 3, 2 and 6 %, respectively (Table 3). 
 
Table 1: Rates of VEGFA gene locus amplification in selected tumour types as 
evaluated by FISH 
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Table 2: Rates of VEGFA: Rates of VEGFA gene locus amplification in the analysed 
tumour types as evaluated using FISH. 
 
 
Figure 7: Visualization of VEGFA gene locus 6p12 amplification by FISH. The green 
and red signals correspond to centromere 6 and VEGFA gene region, respectively. a 
Representative pictures of gastric cancer with normal and b amplified VEGFA gene 
status. c Representative pictures of lung cancer with normal and d amplified VEGFA 
gene status. 
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Table 3: Rates of VEGFA gene locus amplification using the alternative cut off 
criterion in selected tumour types as evaluated using FISH 
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Table 4: Rates of VEGFA gene locus amplification using the alternative cut off 
criterion in the analysed tumour types as evaluated using FISH. 
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Furthermore, across the all tumour species analysed, the sum of cases with either 
focal VEGFA gene amplification and/or polysomy of Chr6 revealed prevalence rates 
up to 16 % (endometrium–serous carcinoma, Table 3). As expected neither genomic 
amplification of VEGFA nor polysomy was detected in any of the normal control 
samples (Table 4). 
Finally, in order to investigate whether VEGFA amplification induces increased vessel 
density as a result of VEGFA overproduction, we performed MVD IHC-based 
evaluation on a small cohort of CRCs (total n = 10, not amplified n = 3, polysomic 
n = 4, amplified n = 3) specimens using CD31 as marker of blood vessels. 
Representative pictures of CD31 staining are presented in Fig. 7a. Our analysis 
revealed that CRC samples harbouring VEGFA amplification present with increased 
MVD compared to both not amplified and polysomic specimens (Fig. 8b). 
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Figure 8: Micro-vessels density is increased in CRC VEGFA amplified samples. a 
Representative pictures of CD31 stained CRC specimens. Scale bar correspond to 
100 µm. b MVD quantification 
 
2.7.2 Analysis of the VEGFA gene amplification by FISH on TMA and high 
resolution CGH microarrays in human tumour xenografts 
To confirm the presence of the VEGFA gene amplification by an independent 
method, we analysed 194 fresh-frozen tissue specimens obtained from human 
tumour-derived xenografts using CGH. The VEGFA gene locus status of these 194 
models was previously analyses using corresponding FFPE samples by means of 
our FISH probe. FISH analysis revealed 4 samples harbouring VEGFA amplification 
namely specimens obtained from gastric, breast, non-small-cell lung cancer (NSCLC) 
and sarcoma, with prevalence rates between 5 and 16 % (Table 5 and Table 6 for 
complete listing). In addition, as for the human multi tumour-TMA above described, 
we have further categorized the amplified samples using a second selection criterion 
discriminating between high (i.e. >10 VEGFA/Chr6), average (5–10 VEGFA/Chr6) or 
low number of gene copies (Table 7 and Table 8). FISH results were confirmed for all 
4 samples by CGH. Figure 9 displays representative high-resolution CGH microarray 
profiles of one melanoma without amplification and two VEGFA amplified tumours (a 
gastric cancer and NSCLC). By means of CGH analysis, we also investigated the 
structure of the VEGFA amplicon. Whereas the gastric cancer sample (Fig. 9b) 
showed a larger amplified region (approx. 20 Megabases), the NSCLC sample 
(Fig. 9c) was characterized by a focal amplicon covering a small region of 5.85 Mb. 
 
Table 5: Rates of VEGFA gene locus amplification in selected human tumour 
xenografts as evaluated by FISH 
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Table 6: Rates of VEGFA gene locus amplification in human analysed tumour 
xenografts as evaluated by FISH 
 
 
Table 7: Rates of VEGFA gene locus amplification in human selected tumour 
xenografts using the alternative cut off criterion as evaluated by FISH 
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Table 8: Rates of VEGFA gene locus amplification in human tumour xenografts using 
the alternative cut off criterion as evaluated by FISH 
 
 
 
Figure 9: Representative CGH profiles of the VEGFA genomic region. Depicted area 
focus on Chromosome 6—VEGFA locus. a Melanoma sample with normal VEGFA 
gene copy number. b, c Gastric cancer and NSCLC samples showing VEGFA gene 
amplification, respectively. Red arrows point towards the VEGFA gene position at 
6p12. The vertical dotted red line denotes the position of the centromere of the 
Chromosome. Horizontal blue lines represent the segments inferred by the CGH 
calling algorithm. 
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In addition, we investigated the copy number status of Chr6 and observed polisomy 
in 6 of the 24 analysed tumour types such as bladder, colon and small cell lung 
cancer, pleura mesothelioma, NSCLC and NSCLC of the squamous cell subtype 
(Table 7 and Table 8). Moreover our analysis revealed that among all tested tumour 
types only NSCLC, showed both amplified and polysomic cases. 
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Chapter III 
VEGFA gene locus amplification in colorectal cancer and response to 
Bevacizumab treatment. 
3.1 Materials and Methods 
3.1.1 CRC Patients 
A cohort of 86 patients with CRC diagnosed at the Cantonal Hospital of Aarau 
(Zentrum für Onkologie, Hämatologie u. Transfusionmedizin, Kantonsspital Aarau) 
and at Cantonal Hospital St.Gallen, were analysed into this study.  
All pateints have been treated with surgical resection and selected according to: 
• Histologically or cytologically confirmed metastatic colorectal cancer (CRC). 
• First-line chemotherapy with oral or intravenous fluoropyrimidine alone, or in 
combination with irinotecan or oxaliplatin. Chemotherapy must have been 
given in combination with standard dose of bevacizumab for at least 16, but 
not longer than 24 weeks as part of the first-line treatment for metastatic CRC. 
• Stable disease (SD), partial response (PR) or complete response (CR) after 
end of chemotherapy/bevacizumab first-line treatment. 
• No anti-EGFR-antibody treatment (e.g. cetuximab) during first-line treatment. 
 
After all patients have been stratified as following: 
 
Clinico-pathological information included age, pT classification, pN classification, pM 
and tumor grade were available for the most of the patients (Table 9). All 
histomorphological data were reviewed from the corresponding hematoxylin and 
eosin (H&E)-stained slides. 
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Clinicopathological features 
Age (years range) 23-76 
Gender 
female  35 
male 51 
Tstage 
pT1-2 5 
pT3-4 35 
Nstage 
pN0 5 
pN1-2 30 
Tumor grade 
G1-2 15 
G3 8 
Metastasis 
Absent 72 
Present 14 
Kras mutations 
G12A 8 
G12C 1 
G12D 2 
G12R 1 
G12V 5 
G13D 2 
G13R 1 
Negative 25 
 
Table 9: Clinico-pathological features of colorectal cancer patients. 
 
3.1.2 RECIST criteria 
The assessment of efficacy of bevacizumab-based therapy relies on Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria (118). According to these 
criteria, response is measured on a patient based level, determined as the total 
change in sum of diameters of all pre-defined target lesions following treatment. 
Patients are then classified into one of four categories: complete response (CR), 
partial response (PR), progressive disease (PD) and stable disease (SD) (119). The 
RECIST criteria have been validated, are well-described, easy to use, implemented 
worldwide and useful for evaluation of response in clinical studies to identify patients 
showing disease progression. However, the RECIST criteria apply rather broad cut-
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off values for the different response categories, thereby grouping large cohorts of 
patients who might show rather significant differences in response to therapy and 
possibly also in survival. This influences the accuracy of treatment efficacy 
evaluation. Furthermore, the RECIST criteria do not take into account individual 
lesion response, while several studies have demonstrated variations in intratumoural 
genetic alterations between different metastatic lesions within a single patient, 
suggesting differences in tumoural behavior between metastases. 
3.1.3 Tissue sections 
To assess the VEGFA gene amplification by FISH (Fluorescent in situ Hybridization) 
whole tissue sections from patients, treated with chemotherapy plus bevacizumab 
between 2003 and 2007 at the Hospital of Aarau and Hospital of St. Gallen were 
selected according to the response to the BV. Usage of the clinical samples for tissue 
microarray construction was approved by the ethical committee of the University of 
Basel and Aarau and St. Gallen hospital. 
3.1.4 Preparation of FISH probe 
The genomic BAC clone RPCIB753M0921Q (imaGENES GmbH, Berlin, Germany), 
which covers the VEGFA genomic region (6p12) was used for preparation of the 
FISH probe. A starter culture of 2-5 ml LB medium was inoculated with the BAC 
clone and 0.5 ml of the starter culture was diluted in 500 ml selective LB medium. 
BAC-DNA was isolated using the Large-Construct Kit (Qiagen, Hombrechtikon, 
Switzerland) according to the manufacturer’s instructions. BAC identity was verified 
by sequencing using 1 µg of isolated DNA and 20 pmol of SP6, using T7 primers 
(EuroFins MGW Operon, Ebersberg, Germany). 1µg of isolated BAC-DNA was 
digested with Alu I restriction enzyme (Invitrogen, Lucerne, Switzerland) and labelled 
with Cy3-dUTP (GE Healthcare, Buckinghamshire, UK) using the BioPrime Array 
CGH Kit (Invitrogen, Lucerne, Switzerland). Labeling reaction was assessed by 
usage of a Nanodrop assay (Nanodrop, Wilmington, USA). The labelled DNA was 
purified by using the FISH Tag DNA Kit (Invitrogen, Lucerne, Switzerland).  
3.1.5 FISH analysis 
86 FFPE whole tissue sections were subjected to pre-treatment as previously 
described (105). FISH probe was applied and after a denaturation step (10 minutes 
at 75°C), the slides were incubated over night at 37°C. Slides were afterward washed 
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with Washing Buffer (2X SSC, 0.3% NP40, ph 7-7.5) and slides were counterstained 
with DAPI I solution (1000 ng/ml) (Vysis Inc. Abbott Molecular, Abbott Park, USA). As 
reference, a Spectrum Green-labelled chromosome 6 centromeric probe (Vysis Inc. 
Abbott Molecolar, Abbott Park, USA) was used. Images were obtained by usage of a 
Zeiss fluorescence microscope using a 63X objective (ZEISS, Feldbach, Switzerland) 
and the Axiovision software (ZEISS, Feldbach, Switzerland). A minimum of 100 
tumour nuclei signals in four separate regions of the tissue section was counted. 
FISH results were interpreted according to: (1) absolute VEGFA gene copy number 
or (2) the ratio VEGFA gene/Chr6 copy number. We classified as not amplified 
samples with a VEGFA/Chr6 ratio of less than 1.8; equivocal/borderline with a 
VEGFA/Chr6 ratio between 1.8 and 2.2, amplified with a VEGFA/Chr6 ratio higher 
than 2.2, as proposed by the ASCO/CAP guidelines for HER2 amplification in breast 
cancer (120). Polysomy of chromosome 6 was defined as an average of the 
chromosome 6 copy number. When the average was included between 2.26-3.75, 
the polysomy 6 was defined as low whereas, when the average was > 3.75 the 
polysomy 6 was defined high (109-112). 
 
3.2 Results 
3.2.1 VEGFA gene amplification in CRC patients selected according to 
response to adjuvant Bevacizumab in combination with chemotherapy 
To demonstrate the potential role of VEGFA gene amplification and increased gene 
copy number as predictive biomarker of clinical response to BV in colorectal cancer, 
we enrolled a total of patients treated with Bevacizumab in addition to chemotherapy 
(5fluorouracil, leucovorin, capecitabine, oxaliplatin, mephedrone). 51 were male and 
35 were female. The age was comprised between 23-76 years. (Table 9) The 
patients were stratified according to TNM classification as reported in Table 9 and 
they were selected on the basis of their response to bevacizumab, according to 
RECIST criteria. 14 were classified as responders and 72 as not-responders. The 
length of the therapy with bevacizumab was comprised between 14-511 days. 13 of 
86 patients (15.1%) showed a significant response to Bevacizumab, whereas 73 of 
86 patients (84.9 %) had disease progression. We performed the FISH analysis of 86 
colorectal cancer patients in a blinded manner. VEGFA gene amplification was 
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observed in specimens of four patients (4.65 %) of 86 patients. The high polysomy 6 
was observed in 10 (11.63 %) of 86 patients and the low polysomy in 13 (15.11 %) of 
86 patients. The amplification, high polysomy and low polysomy were not found in 59 
(68.6 %) of 86 patients. The high polysomy and low polysomy were observed in 
combination with VEGFA gene amplification in one and two cases, respectively. The 
four patients harbouring VEGFA gene locus (6p12) amplification in their primary CRC 
showed a significant differential response to BV treatment compared to patients with 
no gene amplification or either low/high polysomy. Indeed all four patients (100%) 
with VEGFA gene amplification were found to be responders; only 4 (40%) out of 10 
patients and 5 (38%) out of 13 patients harbouring high polysomy and low polysomy 
of chromosome 6, respectively responded to BV. Only 1 (1.69%) out of the 59 
patients with normal VEGFA gene presence seemed to profit from BV treatment 
(Figure 10). 
3.2.2 Statistical analysis  
The VEGFA gene amplification influence on the response to BV was calculated by 
means of logistic regression. The observed dependent variable being zero in case of 
absence and one in case of response to BV. The predicted value of the logit was 
converted into predicted odds via the inverse of the natural logarithm, namely the 
exponential function. Two-tailed P-values <0.05 were regarded as significant for all 
analyses. Statistical analyses were performed using R i386 Version 2.15.2 
(http://www.R-project.org). Logistic regression analysis of these data is significant 
p<0.000001 and indicates an increase in response 1.29 (1.22-1.38) folds depending 
on the VEGFA gene status. These results suggest that VEGFA gene locus 
amplification could modulate CRC patients’ response to BV treatment depending on 
its genomic levels. 
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Figura 10: Histogram indicating the percentage of patients responding or not 
responding to BV treatment in combination with chemotherapeutics. Each plot 
represents a subset of patients according to their VEGFA gene presence (normal, 
low-, high- polysomy, VEGFA amplification). 
 
3.2.3 Oncogenomic studies of a mouse model and human patients reveal a 
biomarker for sorafenib response in hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality 
worldwide, with the highest increase rate in northern America (121-124). Sorafenib is 
the mainstay of therapy for advanced HCC and the only drug that has shown any 
survival advantage in HCC so far (125, 126). However, patient’s response is modest, 
and sorafenib treatment is associated with side effects (125-129). Thus, several 
studies looked for predictive markers for sorafenib response (130-133), yet none 
such biomarkers have yet entered the clinical setting. Predictive biomarkers, 
identifying patient subsets to guide treatment choices, are usually based on distinct 
pathogenetic mechanisms, and are a cornerstone of personalized medicine (134, 
135). Prominent examples include ERBB2 amplification and K-RAS mutations that 
serve as key determinators of treatment with trustuzumab or tetuximab, 
respectively(136, 137). Sorafenib is a multikinase inhibitor, the targets of which 
include: B-Raf, C-Raf, PDGFR2, c-Kit and VEGF receptors (VEGFRs) (131, 138). 
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While VEGFRs were thought to be good candidates, testing for VEGF serum levels 
was not proven predictive (131).  
Here, in collaboration with the Department of Pathology, Hadassah-Hebrew 
University Medical Center, Jerusalem, Israel, we characterize a subset of mouse and 
human HCC harboring genomic gains of VEGF-A. These tumors display distinct 
morphological and biological characteristics. Mouse amplicon-derived VEGF-A 
appears to work via heterotypic paracrine interactions: stromal VEGF receptors 
(VEGFRs) responding to tumor VEGF produce hepatoycte growth factor (HGF) 
reciprocally affecting tumor cells. This is therefore an example of genomic 
amplification driving tumorigenesis indirectly, through the microenvironment. 
Amplicon-positive mouse HCCs respond to VEGF inhibition, with HGF 
downregulation and a sharp decrease in proliferation. Sorafenib, a multikinase 
inhibitor, which is the first-line drug in human HCC targets the VEGFRs, but has only 
an overall mild beneficial effect in HCC. We found that genomic gains in VEGF-A 
specify mouse and human HCCs that are distinctly sensitive to sorafenib, suggesting 
they could serve as a biomarker for HCC response to VEGF-A blocking drugs.  
Previous studies have delineated a hepatocyte-endothelial crosstalk taking place in 
non-neoplsatic liver, wherein VEGF-A stimulates endothelial cells to secrete several 
mitogens including Hepatocyte Growth Factor (HGF) (139, 140). We hypothesized 
that Amppos HCCs exploit this interaction for promoting tumor cell proliferation. 
Following this notion, we detected a 3-fold elevation of HGF mRNA levels in Amppos 
vs. Ampneg HCCs.. We did not find significant changes in other angiocrine produced 
molecules – Wnt2, IL-6 and HB-EGF. Immunostaining detected HGF expression only 
in Amppos tumors, restricted to non-neoplastic tumor infiltrating cells. 
Coimmunofluorescent staining for HGF and F4/80 showed that macrophages are the 
major cell type expressing HGF.  
To understand the VEGFA-HGF relationship we isolated hepatocytes and 
macrophages from Mdr2-/- livers at the age of 8 months, a time point signified by 
marked dysplasia, yet no overt HCC formation (141). mRNA profiling of these 
fractions portrayed that VEGF receptors (FLT1, KDR) and coreceptors (Neuropillin1 
and 2) were higher in macrophages while the HGF receptor c-MET was more 
abundant in hepatocytes. This aligns with previous work showing that hepatocytes 
are inert to direct activation with VEGF-A (139). Immunostaining for KDR in Amppos 
tumors demonstrated that its expression in these tumors is restricted to non-
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neoplastic cells. This correlated with a modest increase in mRNA levels of both KDR 
and FLT1 in total tumor lysates which is comparable to the increase in mRNA levels 
of recruited macrophage and endothelial markers Msr1 and CD105, respectively. 
This suggests that VEGF-A in Amppos tumors does not provide autocrine signals to 
hepatocytes, but rather acts through manipulation of the microenvironment to induce 
HGF secretion by TAMs. 
 
 
3. GENERAL DISCUSSION 
 
VEGFA binds to VEGFR1 and VEGFR2, which are both found predominantly on the 
surface of vascular endothelial cells, inducing vasculogenesis and angiogenesis. 
Studies in vitro suggest that VEGFR1 acts on the cell proliferation, survival and 
permeability and VEGFR2 contributes to cell migration (142, 143). Given its role in 
the growth and development of different tumor types, VEGFA is considered the most 
attractive target of anticancer therapy. The use of BV as antiangiogenic cancer 
treatment has been intensively reported and discussed in the literature. In 2004, 
Hurwitz et al report on a benefit for patients suffering from metastatic colorectal 
cancer (mCRC) when its administration is combined with chemotherapy (144). 
Recent data of several clinical trials, including more than 3000 patients, seem to 
confirm that the combination of BV and chemotherapy (Irinotecano, Fluorouracil, 
Leucovorin, Oxaliplatin) improves the progression – free survival (PFS) and the 
overall survival (OS) (145-147). However, only a subset of patients (22%) has a 
benefit, as compared with chemotherapeutic treatment alone (8.6%) and BV – based 
therapy alone (3.3%) (145-147). Besides CRC, BV has been used as antitumor agent 
in several other tumor types: Miller et al (148) showed that the early treatment with 
chemotherapy plus BV in the course of metastatic breast cancer prolongs the PFS 
and the objective response rate (ORR), but not the OS, when it is compared with 
paclitaxel alone. Sandler et al (149) reported a benefit of BV in addition of 
chemotherapeutic treatment (paclitaxel plus carboplatin) in selected patients with 
non-small-cell-lung-cancer (NSCLC). In fact, they showed a significant improvement 
in OS, PFS and ORR, but with the risk of increased deaths related to treatment. In 
patients with metastatic renal cell cancer (RCC), administration of high dose of BV 
led to significant increases of the time of disease progression, but not the OS. 
However, no significant difference was observed in patients who had received low-
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dose of the drug and placebo (150). In patients with unresectable hepatocellular 
carcinoma (HCC), administration of BV led to an objective response rate only in 13% 
of the patients. However, a substantial part of patients showed evidence of minor 
tumor regression (151). At the moment BV is approved by the US Food and Drug 
Administration (FDA) for the treatment of mCRC, NSCLC and RCC. It remains 
approved for the treatment of metastatic breast cancer as well in multiple countries 
throughout the world, based largely on the results of the E2100 trial. In addition, anti-
VEGF therapy with BV and other agents remains important for other tumor types 
(26–31). However, predictive biomarkers that identify which patients derive benefit 
and toxicity from anti-angiogenic agents are still needed (32).  
The work presented here has been mainly focused on genomic aberrations of 
VEGFA. We analyzed a first cohort of 1420 patients with primary colorectal cancer 
diagnosed at the Institute of Pathology, University Hospital Basel, Institute of Clinical 
Pathology, Basel; a second cohort of 221 nonconsecutive patients treated at the 4th 
Department of Surgery, University of Athens Medical School, randomly selected from 
the archives of the 2nd Department of Pathology, University of Athens Medical 
School (Attikon University Hospital), Greece. On a total number of 1501 primary 
unselected CRC patients we observed VEGFA gene locus amplification in 3% to 6% 
of two independent cohorts, respectively. The genomic aberration, in both cohorts, 
was significantly associated with unfavorable prognostic features and poorer survival 
time (152). Afterwards, we wanted to address whether VEGFA locus amplification is 
a phenomenon limited to CRC or it is a common alteration in several tumor types. We 
assessed the VEGFA gene copy number status in a total of 2837 tumors and 315 
normal tissue specimens and we identified that VEGFA amplification is presented 
regularly in several tumor entities but with low incidence and it was always absent in 
normal tissues. The prevalence rates of VEGFA amplification in these tumors varied 
between 1.5% and 5%, based on CGH profiling studies, gain of chromosome 6p has 
been described in different tumor types, such as hepatocellular carcinoma, 
osteosarcoma, retinoblastoma, Merkel cell carcinoma and carcinosarcoma (153). 
Additionally, focal gain and amplification of the VEGFA gene was also reported in 4 
out of 103 hepatocellular carcinomas (154) and in 4 out of 371 lung cancers (155, 
156). Our study was as well motivated by the hypothesis that the VEGFA gene 
amplification could be useful as predictive biomarker of clinical response in patients 
considered for BV or tyrosine kinase inhibitors treatment in addition to chemotherapy. 
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To investigate how VEGFA gene locus amplification modulates CRC patients’ 
response to BV treatment a cohort of 86 patients with CRC diagnosed at the 
Cantonal Hospital of Aarau and Cantobal Hospital l of St. Gallen with adjuvant BV 
treatments in combination with chemotherapeutic agents and known outcome were 
entered into our study. We found that CRC patients carrying the VEGFA gene locus 
amplification respond better to BV treatment compared to patients with no gene 
amplification. Despite if the biological mechanism is still to be elucidated it is tempting 
to speculate that the positive response to bevacizumab could act as already 
observed for HER2 amplification and response to trastuzumab in breast and gastric 
cancer. Slamon et al. (157) first described the importance of HER2 in breast cancer 
in 1987 now it is well assessed its prognostic and predictive significance (158). 
Indeed, the HER2/neu overexpression is closely related to gene amplification in 
breast, ovarian, bladder, and stomach cancer (157) and it has been associated in 
20% to 30% of breast cancers with a poor prognosis (157, 159). HER-2/neu 
overexpression/amplification has become clinically important in the management of 
metastatic breast cancer patients given to the availability of a humanized specific 
monoclonal antibody, trastuzumab (Herceptin, Roche, Basel, Switzerland), which has 
significant antitumor activity in these patients both as a single agent and in 
combination with chemotherapy (160, 161). For clinical HER-2/neu status 
determination immunohistochemistry according to the FDA-approved scoring system 
(0, 1+, 2+, and 3+) detects HER-2/neu protein overexpression whereas fluorescence 
in situ hybridization (FISH) assesses HER- 2/neu gene copy amplification. Both 
methods are recommended by national and international guidelines (162). The 
evaluation of genetic numerical aberration in tumor specimens is already a 
meaningful tool to predict response to therapy; therefore our results will pave the way 
to better understand the mechanism beside BV responses in order to reach 
personalized BV treatment modalities. This last point constitutes one of the most 
debated problems concerning cancer patients’ treated with BV, also considering the 
monetary cost and toxicity of BV administration. Concerning mCRC treatment, BV 
has clearly demonstrated its efficacy. Nevertheless, since patients respond to this 
therapy in different manners, there is an urgent need to improve the understanding of 
its mechanism of action. Indeed, a constantly increasing number of preclinical studies 
are generating new insights in the mechanism of acquired resistance or intrinsic 
refractoriness to anti-angiogenic agents. Taking advantage of our experience with 
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human samples, with this project we aimed to validate preclinical data and set the 
basis for a future investigation concerning anti-angiogenic therapy resistance. With 
this work, we also validated the reliability of FISH test as a diagnostic tool to assess 
the VEGFA gene status. To conclude, if our preliminary data and future working 
hypotheses will be confirmed, CRC patients will greatly benefit from our research 
activities. Altogether, our research may lead to innovative personalized therapeutic 
strategies for those patients with aggressive forms of CRC disease which do not 
respond to anti-angiogenic therapies. 
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4. Appendix 
General background on hepatocellular carcinoma 
Unlike most malignancies, mortality from liver cancer has increased significantly over 
the past 20 years and epidemiologic evidence indicates that the medical and 
economic burden of liver cancer will increase significantly in Western populations 
during the next decades (163). Hepatocarcinogenesis is a multi-step process 
involving different genetic alterations that lead to malignant transformation of the 
hepatocyte (121). Most HCCs arise in a cirrhotic liver (164) and worldwide around 
80% of them are related to a chronic infection with either hepatitis B (HBV) or 
hepatitis C virus (HCV) (165). Moreover, a rising proportion of HCCs is ascribed to 
alcohol abuse and metabolic disorders (166-168). In the last years, the extensive 
heterogeneity of genomic lesions reported in HCCs have suggested that liver cancer 
is the result of a combination of both, genetic and epigenetic, alterations which affect 
more than one regulatory pathway (124, 135, 169-175). Among these pathways the 
best described are Wnt/β-catenin, MAPK, p14ARF/p53, p16INK4A/Rb, transforming 
growth factor-β (TGF-β) and PTEN/Akt (163). In addition, previous studies have 
identified several oncogenes associated with HCC, such as MDM4 (1q32), MYC 
(8q24), Jab1 (8q), cIAP1, and Yap (11q22) and tumor suppressor genes such as 
DLC1 (8p22), RB1 (13q14), and TP53 (17p13) (176-179). Furthermore, comparative 
genomic hybridization (CGH) has shown frequent DNA copy number gains at 
chromosomes 1q, 8q and losses at 1p, 4q, 8p, 13q, 16q and 17q in HCC specimens 
(121, 180-183). Interestingly, the chromosomal region surrounding 8p21-23 has been 
shown to be frequently lost in colorectal cancer (CRC) and other solid tumors (184) 
and thus has been generally linked to carcinogenesis (185). More recently, using an 
integrative approach of high-resolution array-based CGH and gene expression 
profiling, Roessler et al. characterized some of the genes located at 8p in HCC 
samples (180). Among these, SH2D4A (8p21.3) encodes for SH(2)A. 
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